...
首页> 外文期刊>Cellular Physiology and Biochemistry >Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing
【24h】

Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing

机译:使用microRNA测序的耐药性非小细胞肺癌细胞系中microRNA的表达谱

获取原文
           

摘要

Background/Aims Drug resistance remains a main obstacle to the treatment of non- small cell lung cancer (NSCLC). The aim of this study was to identify the expression profiles of microRNAs (miRNAs) in drug-resistant NSCLC cell lines. Methods The expression profiles of miRNAs in drug-resistant NSCLC cell lines were examined using miRNA sequencing, and the common dysregulated miRNAs in these cell lines were identified and analyzed by bioinformatics methods. Results A total of 29 upregulated miRNAs and 36 downregulated miRNAs were found in the drug-resistant NSCLC cell lines, of which 26 upregulated and 36 downregulated miRNAs were found to be involved in the Ras signaling pathway. The expression levels, survival analysis, and receiver operating characteristic curve of the dysregulated miRNAs based on The Cancer Genome Atlas database for lung adenocarcinoma showed that hsa-mir-192, hsa-mir-1293, hsa-mir-194, hsa-mir-561, hsa-mir-205, hsa-mir-30a, and hsa-mir-30c were related to lung cancer, whereas only hsa-mir-1293 and hsa-mir-561 were not involved in drug resistance. Conclusion The results of this study may provide novel biomarkers for drug resistance in NSCLC and potential therapies for overcoming drug resistance, and may also reveal the potential mechanisms underlying drug resistance in this disease.
机译:背景/目的耐药性仍然是非小细胞肺癌(NSCLC)治疗的主要障碍。这项研究的目的是鉴定耐药性NSCLC细胞系中microRNA(miRNA)的表达谱。方法采用miRNA测序技术检测耐药NSCLC细胞中miRNA的表达情况,并通过生物信息学方法鉴定和分析这些细胞中常见的失调miRNA。结果在耐药NSCLC细胞株中共发现29个上调的miRNA和36个下调的miRNA,其中26个上调的miRNA和36个下调的miRNA与Ras信号通路有关。基于癌基因组图谱数据库的肺腺癌失调的miRNA的表达水平,存活分析和受体工作特性曲线显示,hsa-mir-192,hsa-mir-1293,hsa-mir-194,hsa-mir- 561,hsa-mir-205,hsa-mir-30a和hsa-mir-30c与肺癌有关,而仅hsa-mir-1293和hsa-mir-561与肺癌无关。结论这项研究的结果可能为NSCLC的耐药性提供新的生物标记物,并为克服耐药性提供潜在的疗法,也可能揭示该疾病耐药性的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号